Compare LCID & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCID | TLX |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Australia |
| Employees | N/A | 1184 |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.6B |
| IPO Year | 2020 | N/A |
| Metric | LCID | TLX |
|---|---|---|
| Price | $6.04 | $10.57 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $15.71 | ★ $21.13 |
| AVG Volume (30 Days) | ★ 19.9M | 126.5K |
| Earning Date | 05-05-2026 | 08-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,271,000.00 | N/A |
| Revenue This Year | $71.67 | N/A |
| Revenue Next Year | $89.72 | N/A |
| P/E Ratio | ★ N/A | $150.33 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.97 | $6.28 |
| 52 Week High | $25.22 | $18.13 |
| Indicator | LCID | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 52.20 |
| Support Level | $5.62 | $9.46 |
| Resistance Level | $6.77 | $11.28 |
| Average True Range (ATR) | 0.41 | 0.29 |
| MACD | 0.11 | -0.11 |
| Stochastic Oscillator | 34.78 | 28.77 |
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.